Charles N. Ellis, M.D.

Professor, Department of Dermatology

Selected Publications

1. Ellis CN, Gorsulowsky DC, Hamilton TA, Headington JT, Cooper KD, Baadsgaard O, Duell EA, Annesley TM, Turcotte JG, Voorhees JJ: Cyclosporine improves psoriasis in a double-blind study. JAMA 1986; 256:3110-3116. (Selected for reprinting in 4 international editions.)
2. Ellis CN, Voorhees JJ: Etretinate therapy. J Am Acad Dermatol 1987; 16:267-291. (Lead CME article)
3. Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ: Topical tretinoin improves photoaged skin: A double-blind vehicle-controlled study. JAMA 1988; 259:527-532. (Selected for reprinting in international edition.)
4. Woodley DT, Zelickson AS, Briggaman RA, Hamilton TA, Weiss JS, Ellis CN, Voorhees JJ: Treatment of photoaged skin with topical tretinoin increases epidermal-dermal anchoring fibrils: A preliminary report. JAMA 1990; 263:3057-3059.
5. Eisen DE, Ellis, CN, Duell EA, Griffiths CEM, Voorhees JJ: Effect of topical cyclosporine rinse on oral lichen planus: A double-blind analysis. N Engl J Med 1990; 323:290-294.
6. Ellis CN, Weiss JS, Hamilton TA, Headington JT, Zelickson AS, Voorhees JJ: Sustained improvement with prolonged tretinoin (retinoic acid) for photoaged skin. J Am Acad Dermatol 1990; 23:629-637.
7. Ellis CN, Fradin MS, Messana JM, Brown M.D., Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG, Ellis-Madu M, Duell E, Annesley TM, Cooper KD, Voorhees JJ: Cyclosporine for plaque-type psoriasis: Results of a multidose, double-blind trial. N Engl J Med 1991; 324:277-284. (Selected as subject of editorial.)
8. Rafal ES, Griffiths CEM, Ditre CM, Finkel LJ, Hamilton TA, Ellis CN, Voorhees JJ: Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. N Engl J Med 1992; 326:368-374.
9. Bulengo-Ransby SM, Griffiths CEM, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, Voorhees JJ: Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med 1993; 328:1438-1443. (Selected as subject of editorial.)
10. Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ: Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995;131:791-795. (Selected as subject of editorial.)
11. Javier AF, Bata-Csorgo Z, Ellis CN, Kang S, Voorhees JJ, Cooper KD: Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Inv 1997; 99:2094-2099.
12. Ellis CN, Stevens SR, Blok BK, Taylor RS, Cooper KD: Interferon- therapy reduces blood leukocyte levels in patients with atopic dermatitis: Correlation with clinical improvement. Clin Immunol 1999; 92:49-55.
13. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, Chi Y, Kurtz TW: Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 2000; 136:609-616.
14. Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory-effector T lymphocytes. N Engl J Med 2001; 345:248-255. (Selected as subject of editorial)
15. Ellis CN, Reiter KL, Wheeler JRC, Fendrick AM: Economic analysis in dermatology. J Am Acad Dermatol 2002; 46:271-83.
16. Ellis CN, Drake LA, Prendergast MM, et al: Cost of eczema and atopic dermatitis in the United States. J Am Acad Dermatol 2002; 46:361-70.
17. Ellis CN, Drake LA, Prendergast MM, et al: Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema. Pharmacoeconomics 2003; 21:875-883.
18. Bhagavathula N, Nerusu KC, Lal A, Ellis CN, Chittiboyina A, Avery MA, Ho C I, Benson SC, Pershadsingh HA, Kurtz TW, Varani J: Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol 2004; 122:130-9.
19. Langley RG, Ellis CN: Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:563-9.
20. Ellis CN, Pillitteri JL, Kyle TK, Ertischek M.D., Burton SL, Shiffman S: Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone. J Am Acad Dermatol 2005; 53:41-51.
21. Bhagavathula N, Nerusu KC, Reddy M, Ellis CN, Chittiboyina A, Avery M, Pershadsingh HA, Kurtz TW, Varani J: BP-1107 [{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application. J Pharmacol Exp Ther 2005; 315:996-1004.
22. Kia KF, Tavakkoli A, Ellis CN: Clinical e-mail in an academic dermatology setting. J Am Acad Dermatol 2006; 54:1019-24.
23. Kia, KF, Gielczyk RA, Ellis CN: Academia is the life for me, I'm sure. Arch Dermatol 2006; 142:911-3. [Editorial and study on residents' predicted and actual career choices.]
24. Varani J, Bhagavathula N, Ellis CN, Pershadsingh HA: Thiazolidinediones: Potential as therapeutics for psoriasis and perhaps other hyperproliferative skin diseases. Expert Opin Investig Drugs 2006; 1453-68.
25. Callen J, Chamlin S, Eichenfield LF, Ellis C, et al: A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007; 156:203-21